Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ANGLE plc ( (GB:AGL) ) just unveiled an announcement.
ANGLE plc announced changes to its Board, with Non-Executive Director Brian Howlett retiring after 12 years and Juliet Thompson resigning immediately. The company is evaluating its Board structure and composition moving forward, which may impact its strategic direction and governance. These changes come as ANGLE continues to focus on its core business of liquid biopsy solutions, potentially affecting its market positioning and stakeholder interests.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £30.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
More about ANGLE plc
ANGLE plc is a world-leading liquid biopsy company that specializes in innovative circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company’s key product, the Parsortix® PC1 System, is FDA cleared and allows for comprehensive downstream analysis of blood samples, including whole cell imaging and molecular analysis. ANGLE focuses on clinical services and diagnostic products, with its services offered through GCLP-compliant laboratories.
Average Trading Volume: 1,252,172
Technical Sentiment Signal: Sell
Current Market Cap: £24.19M
See more insights into AGL stock on TipRanks’ Stock Analysis page.